4th Jan 2017 16:36
Proteome Sciences plc
(the "Company")
Holdings in Company and PDMR Shareholding
Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund ("Vulpes"), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each ("Ordinary Shares") at 5.5 pence per Ordinary Share (the "Transaction"). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,943,715 Ordinary Shares, representing approximately 18.33% of the current issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Vulpes Life Sciences Fund | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Martin Diggle, non-executive director of the Company is a director and partner of Vulpes Life Sciences Fund | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Proteome Sciences plc | ||||
b) | LEI | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1p each | ||||
Identification code | GB0003104196 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) 04 January 2017 |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
105,590 Ordinary Shares of 1 pence each purchased at an average price of 5.5 pence per Ordinary Share | ||||
e) | Date of the transaction | 04 January 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Related Shares:
Proteome